focalinterest.net

AI Summary of Scholarly Research

This page presents an AI-generated summary of a published research paper. The original authors did not write or review this article. [See full disclosure ↓]

Nine-month all-oral tuberculosis regimens showed durable three-year outcomes

Written by

editor@focalinterest.com

in

Research area:public-health-epidemiologyinfectious-diseases

What the study found

The study found that nine-month, all-oral regimens for rifampicin-resistant tuberculosis were associated with durable outcomes three years after treatment ended. Persistent linezolid-related neuropathic or visual symptoms were also still seen in a substantial share of participants.

Why the authors say this matters

The authors conclude that the findings support durable three-year outcomes for these regimens. They also say the persistent neuropathy warrants proactive mitigation, including reducing cumulative linezolid exposure or using linezolid-sparing alternatives when feasible.

What the researchers tested

This was a multicentre, prospective cohort study in China called MDR-Chin. It included 124 adults with culture-confirmed multidrug-resistant or rifampicin-resistant tuberculosis, or pre-extensively drug-resistant tuberculosis, who received one of four nine-month all-oral regimens containing linezolid at 600 mg/day. The researchers assessed efficacy 36 months after treatment completion and tracked persistent linezolid-related neuropathic or visual symptoms lasting at least 24 months.

What worked and what didn't

At 36 months after treatment completion, 111 of 124 participants, or 89.5%, had a favourable outcome, defined as no failure, relapse, or death. There were no significant differences in favourable outcomes among the four regimens. Persistent linezolid-related neuropathic or visual symptoms were reported by 28 of 124 participants, or 22.6%, and foot numbness was the most frequent symptom, reported by 22 participants.

What to keep in mind

The study was non-randomised and observational, so it does not establish causal comparisons between regimens. The abstract does not provide further detail on the causes of symptoms beyond linezolid-related neuropathic or visual effects, and it does not describe additional limitations.

Key points

  • 111 of 124 participants had a favourable outcome 36 months after treatment ended.
  • No significant differences in favourable outcomes were seen among the four regimens.
  • 28 of 124 participants reported persistent linezolid-related neuropathic or visual symptoms.
  • Foot numbness was the most common persistent symptom.
  • The authors suggest reducing cumulative linezolid exposure or using linezolid-sparing alternatives when feasible.

Disclosure

Research title:
Nine-month all-oral tuberculosis regimens showed durable three-year outcomes
Authors:
Liang Fu, Huaifang Shi, Feng Sun, Wenfei Wang, Peize Zhang, Qianting Yang, Yi Cai, Xilin Zhang, Hancheng Liang, Zhaoqing Wang, Juan Xiong, XinChun CHEN, Wenhong Zhang, Guohua Deng
Institutions:
Dongguan People’s Hospital, Fudan University, Huashan Hospital, Huashan Hospital, Shenzhen Third People’s Hospital, Shenzhen Third People’s Hospital, Shenzhen Third People’s Hospital, Shenzhen Third People’s Hospital, Shenzhen Third People’s Hospital, Shenzhen Third People’s Hospital, Shenzhen University, Shenzhen University, Shenzhen University Health Science Center, Shenzhen University Health Science Center, The Fourth People's Hospital
Publication date:
2026-02-24
DOI:
10.1186/s12879-026-12576-4
OpenAlex record:
View
AI provenance: This post was generated by gpt-5.4-mini (OpenAI). The original authors did not write or review this post.

More posts